在林可霉素生物合成过程中铵离子调控作用的酶学研究

在FUS-50L发酵罐内,用林可链霉菌发酵生产林可霉素。研究发现,NH4^＋对林可霉素发酵过程具有显著的调控效应：补入硫酸铵前,发酵液中的NH4^＋浓度由3．0mmol／L消耗至1．0mmol／L以下的控制过程非常关键,这样可能使林可霉素合成酶大量合成,同时,解除了NH4^＋对谷氨酰合成酶（GS）的阻遏效应;20～24h,尽可能提高硫酸铵的平均补入速率,但最高NH4^＋的瞬时浓度应控制在19．0mmol／L以下,一方面可缩短生物量的积累时间,另一方面可避免过高浓度的NH4^＋对GS的抑制作用;24h后逐渐降低NH4^＋的平均补入速率,使主代谢流转入次级代谢;在发酵中期和后期,应将最低NH4^＋浓度控制在3．0～4．0mmol／L的范围内,避免铵离子对GS的阻遏效应,GS比活力与林可霉素的产量呈正相关关系。最终建立了动态的硫酸铵补加工艺。     

林可霉素生物合成及其分子调控研究进展

林可霉素(lincomycin)是由林可链霉菌(Streptomyces lincolnensis)产生的酰胺类抗生素,在临床上主要用于治疗革兰氏阳性菌引起的感染。鉴于其具有高药用价值和经济价值,林可霉素生物合成和分子调控备受关注,并取得了较好的研究进展。本文综述了林可霉素的特征结构和生物合成,并重点介绍了林可链霉菌中林可霉素的分子调控机制等方面的研究进展,有利于深入认识林可链霉菌次级代谢调控网络,为在林可霉素高产菌中改造调控因子或其靶点元件提高产量提供理论指导。     

林可霉素生物合成的研究进展

林可霉素是林可链霉菌(Streptomyces lincolnensis)产生的林可酰胺类抗生素,它抑制细菌细胞的蛋白质合成,临床上主要用于治疗革兰氏阳性菌引起的感染性疾病。林可霉素生物合成基因簇已被克隆和测序。近年来,围绕林可酰胺和丙基脯氨酸的生物合成、调控等进行了深入研究,其硫化反应取得了突破性成果,本文综述了林可霉素生物合成的新进展。     

表面活性剂对林可霉素发酵生产的影响

在林可霉素发酵过程中,当向培养基中加入表面活性剂十二烷基磺酸钠(SDS)、吐温80(Tween 80)和曲拉通(Triton X-100)时,林可霉素的产量受到较大影响。本研究应用响应面设计法(Response surface design)对表面活性剂的配比进行了优化,得到的优化配比为:十二烷基磺酸钠为31.13 mg/100 mL,吐温80为51.97 mg/100 mL,曲拉通为16.9 mg/100 mL。将该优化配比应用于林可霉素发酵,产量提高了36.67%。     

林可霉素生物合成机制研究取得重大突破

<正>《自然》杂志2015年1月14日在线发表了中科院上海有机化学研究所刘文团队在林可霉素生物合成机制方面取得的突破。分子硫醇广泛存在于所有真核和原核生物体系中;长期以来,对其功能的理解局限于对抗各种内源性和外源性因素所引起的细胞氧化还原平衡失调。近日,上海有机所刘文团队的发现显然突破了这一认知"禁锢":小分子硫醇不但可以充当广为人知的"保护性"角色,而且可以前所未有地扮演"建设性"的角色用于指导和参与活性功能分子     

硝酸盐、镁盐对林可霉素生物合成的促进作用

在林肯链霉菌生物合成林可霉素代谢调节的研究中,发现硝酸盐可明显促进林可霉素的生物合成．加入硝酸钾０．８％,林肯链霉菌合成林可霉素的产量可增加３７％．在发酵９６ｈ之前加入硝酸盐均能促进林可霉毒的合成,但产量的增加随加入时间的延迟而降低．硝酸钾在促进产量的同时,使菌体生长减少,看来硝酸盐对林可霉素的合成与菌体生长之间起着调节作用．洗涤菌体试验指出,硝酸盐的加入诱导了林可霉素合成所需要的酶系,这可能是加入硝酸盐后,产生进一步氮代谢的结果;蛋白胨不能代替硝酸盐,进一步说明硝酸钾的作用并不是作为氮源利用．在蛋白质合成抑制剂氯霉素存在下,硝酸盐不再能促进林可霉素的合成,说明氯霉素抑制了硝酸盐或其代谢中间物所诱导的酶系的合成．同时还报导了镁盐促进林可霉素生物合成现象的初步观察结果．硫酸镁在促进林可霉素产量提高的同时,使菌体生长延迟．硫酸镁的这种作用机制可能是通过磷酸镁铵沉淀,降低了培养基中游离氨和可溶性磷酸盐浓度,解除了铵盐和磷酸盐对林可霉素合成的抑制．     

林可霉素生物合成培养基的优化

以花生粉和棉籽蛋白粉取代了原培养基中的黄豆饼粉,采用响应面法对林可霉素产生菌的发酵培养基进行了优化.首先通过单因素试验及正交实验确定替代氮源及其浓度,采用Plackett-Burman实验分析各因素的主效应,选出对响应值影响较大的3个因素,即花生粉、K2HPO4和玉米浆.对这些因素做爬坡实验,确定三个重要因素的中心点浓...     

林可链霉菌黑色素生物合成基因的克隆与表达

以pIJ702的melCl－C2基因为探针杂交林可链霉菌（Streptomyceslincolnensis）78－11染色体DNA,呈现出3．2kb的BamHI片段和2．6kb的SphI片段等一系列阳性条带。构建了含3．0～3．5kbBamHI片段的林可链霉菌78-11基因文库,从中分离克隆了黑色素生物合成基因melCl和melC2,并测定了含有mel基因的重组子pRSB336插入片段的全部DNA顺序。3152bpBamHI片段含有5个开放阅读框架,其中melCl和melC2与链霉菌属三个种的相应基因具有较高的同源性。此外,林可链霉菌78－11的melC2基因产物与人和鼠的酪氨酸酶轻微同源,分别为17．3％和24．5％。种种迹象表明,melCl、melC2和orf3组成黑色素生物合成操纵子结构。为了进一步鉴定上述克隆的林可链霉菌78-11黑色素生物合成基因,构建了分别含有新霉素抗性基因启动子和正反方向mel基因的重组质粒pPZ518和pPZ519,并转化变铅青链霉菌TK23。随机挑选的12个pPZ518转化子在R2YE培养基上均能分泌淡褐色色素,而所有的pPZ519和pES1转化子则都呈白色。     

林可霉素生产中三级种子罐的发酵工艺优化

【背景】林可霉素是一种在临床应用上占有重要地位的林可酰胺类抗生素,关于调控发酵生产中三级种子罐相关参数优化林可霉素发酵工艺的研究较少。【目的】优化林可霉素发酵工艺,提高林可霉素发酵效价及市场竞争力。【方法】对林可霉素生产中三级种子罐的培养基和接种量及三级种子移种菌龄进行优化。【结果】在三级种子罐培养基中葡萄糖、淀粉、玉米浆、黄豆饼粉和硫酸铵浓度分别为64.0、5.0、15.0、14.5和3.5g/L,三级种子罐接种量为25%及三级种子移种菌龄为60h的优化条件下,林可霉素四级发酵效价高达7883U/mL,比优化前效价提高了10%。【结论】对林可霉素生产中三级种子罐相关参数进行调控,初步优化了林可霉素发酵工艺,提高了发酵效价,为优化林可霉素发酵工艺提供了新思路。     

高等植物脱落酸生物合成的酶调控

高等植物ABA的生物合成开始于细胞质内的甲瓦龙酸 (MVA)或位于叶绿体内的丙酮酸_硫胺素焦磷酸 (TPP) ,经一系列反应最后在质体或胞质中形成的。除胁迫或植物发育中生理变化引起的诱导外 ,ABA的合成还受到一系列酶的调控 ,其中 ,玉米黄质环氧化酶 (ZE) ,9_顺环氧类胡萝卜素双加氧酶(NCED)和醛氧化酶 (AO)可能起到重要的调节作用。本文介绍近年来ABA生物合成酶调控的研究进展。     

Regulation of microtubule organization during interphase and M phase

Microtubule (MT) dynamics and organization change markedly during interphase-M phase transition of the cell cycle. This mini review focuses first on p220, a ubiquitous MT-associated protein of Xenopus. p220 is phosphorylated by p34cdc2 kinase and MAP kinase in M phase, and concomitantly loses its MT-binding and MT-stabilizing activities. A cDNA encoding p220 was cloned, which identified p220 as a Xenopus homolog of MAP4, and p220 was therefore termed XMAP4. To examine the physiological relevance of XMAP4 phosphorylation during mitosis, Xenopus A6 cells were transfected with cDNA encoding wild-type or various XMAP4 mutants fused with a green fluorescent protein (GFP). Mutations of serine and threonine within potential phosphorylation sites for p34cdc2 kinase to nonphosphorylatable alanine interfered with mitosis-associated reduction in MT-affinity of XMAP4 and their overexpression affected chromosome movement during anaphase A. These results indicated that phosphorylation of XMAP4 by p34cdc2 kinase is responsible for the decrease in its MT-binding and MT-stabilizing activities during mitosis which are important for chromosome movement during anaphase A. The second focus is on a novel monoclonal antibody W8C3, which recognizes alpha-tubulin. W8C3 stained spindle MTs but not interphase MTs of Xenopus A6 cells, although tubulin dimers in M phase and interphase were equally recognized by this antibody. The difference in MT staining pattern may be because the W8C3-recognition site on alpha-tubulin is sterically hidden in interphase MTs but not in spindle MTs.     

Regulation of EGF-stimulated EGF receptor endocytosis during M phase

It has been generally accepted that endocytosis is inhibited during mitotic phase (M phase) as a means to insulate the cell from outside influences. Many endocytic/trafficking proteins are present during M phase, but are associated with partners that are distinct from those involved in trafficking pathways. These findings have led to the 'moonlighting' hypothesis. However, all these findings are based on the study of fluid-phase and constitutive endocytosis. Here, we used epidermal growth factor receptor (EGFR) as a model system to study ligand-induced receptor endocytosis in M phase. We found that EGF-induced EGFR endocytosis still occurs during M phase, but follows different kinetics. EGF-induced EGFR endocytosis is delayed/inhibited for a few minutes and is slower in M phase, especially at metaphase. However, consistent with previous reports, transferrin endocytosis is inhibited under the same conditions. We further showed that EGFR endocytosis is differentially regulated during the cell cycle: dependent on EGFR kinase activation in M phase, but independent of EGFR kinase activation in interphase. We conclude that cells have adopted a system for selective endocytosis in M phase.     

Expression of steroidogenic acute regulatory protein mRNA in rat placenta during mid-late pregnancy

The production of a steroid hormone in the placenta is essential for maintaining the pregnancy and developing the fetus during gestation. In various steroidogenic tissues (including gonads and adrenal cortex), the steroidogenic-acute-regulatory protein (StAR) acutely transfers cholesterol from the outer to the inner mitochondrial membrane for rapid steroidogenesis. Although steroid hormones were synthesized in the rat placenta, the developmental expression of StAR has been poorly understood in the rat placenta during mid-late pregnancy. Therefore, the aim of the present study was to establish the expression and localization of StAR mRNA in the rat placenta during mid-late pregnancy using Northern blots and in situ hybridization. The Northern blot analysis showed that the StAR mRNA expression significantly changed as the gestation day (GD) progressed. The placental expression of StAR mRNA increased between GD 11 and 13, and then slightly decreased until term. In situ hybridization showed a strong StAR expression in giant trophoblast cells on GD 11 and 13, and a moderate expression in trophoblast and stroma cells within the villi of the labyrinth zone throughout the pregnancy. In this study, we reveal for the first time the existence of StAR mRNA in steroidogenic cells of the placenta during mid-late pregnancy. In conclusion, our results suggest that StAR may regulate steroidogenesis in the rat placenta to maintain the pregnancy and developing the fetus.     

Use of lincomycin to control respiratory infections in lambs: Effects on health and production

The efficacy of lincomycin to control respiratory infections in lambs was assessed in two trials. In trial I, 72 lambs with active mycoplasmal pneumonia were allocated as follows: lambs in group T2 were treated with lincomycin (5 mg kg⁻¹ bodyweight, intramuscularly) twice 2 days apart, those in group T3 with lincomycin (5 mg kg⁻¹ bodyweight, intramuscularly) thrice with 2-day intervals, those in group O with oxytetracycline (20 mg kg⁻¹ bodyweight, intramuscularly) twice 4 days apart and those in group C were controls. In trial II, 48 25–30-day-old clinically healthy lambs were allocated as follows: lambs in group P2 received two injections of lincomycin (5 mg kg⁻¹ bodyweight, intramuscularly) when 30- and 60-day-old, lambs in group P1/30 received one injection of lincomycin (5 mg kg⁻¹ bodyweight, intramuscularly) when 30-day-old, lambs in group P1/60 received one injection of lincomycin (5 mg kg⁻¹ bodyweight, intramuscularly) when 60-day-old and lambs in group C were controls. In trial I, treatment with lincomycin was associated with improved clinical scores; clinical cure rate 42 days after treatment was 87%, 100%, 87% and 0% for group T2, T3, O and C, respectively (P < 0.001); treated lambs produced 18.5% (T2) or 26.5% (T3) heavier carcass than controls; no lung lesions were seen in group T3 lambs, whilst they were evident in 22% of group T2 or group O lambs and in 72% of control lambs; microorganisms were isolated from lung tissue samples of 5 group C and 1 group O lambs. In trial II, administration of lincomycin was associated with smaller clinical scores; prevalence rate of respiratory disorders at the end of the trial was 17%, 42%, 42% and 58% for group P2, P1/30, P1/60 and C, respectively (P < 0.01); treated lambs were >4.5% heavier than controls; lung lesions were recorded in 1 group P2, 2 group P1/30 and group P1/60 and 5 group C lambs; microorganisms were isolated from 1 group P2, 3 group P1/30, 2 group P1/60 and 5 group C lambs. It is concluded that administration of lincomycin is effective for the treatment and the prevention of mycoplasmal atypical pneumonia in lambs.     

Caveolin-1 immuno-expression in human fetal tissues during mid and late gestation

Caveolin-1 (Cav-1) is the main protein in caveolae, and serves as a scaffolding protein onto which many classes of signalling molecules are assembled. Through interaction with proto-oncogene products, Cav-1 may suppress cell proliferation; or when phosphorylated, may also stimulate cell growth. The aim of this study was to determine Cav-1 expression in human fetal tissues, tissues composed of cells undergoing growth and differentiation processes which require a nurturing environment provided by transmembrane vesicular transport. By using immunohistochemistry, Cav-1 was detected in several fetal tissues during mid- and late gestation (from 14 to 39 weeks). The protein was present in adipocytes, endothelial cells, smooth muscle fibers and in a number of sites with a pattern of distribution similar to that of the adult. Intriguingly, a positive immunoreaction for Cav-1 was also noticed in tissues, such as the urothelium, which normally do not express this protein in adulthood. This unexpected pattern of Cav-1 in human fetus may predict novel roles for Cav-1 during fetal development.